Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed Conditions
Information source: Roxane Laboratories
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Essential Hypertension
Intervention: perindopril erbumine (Drug)
Phase: N/A
Status: Completed
Sponsored by: Roxane Laboratories
Summary
The objective of this study was to prove the bioequivalence of Perindopril Erbumine 8 mg
tablet under fed conditions
Clinical Details
Official title: A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Perindopril Erbumine Tablets 8 mg Under Fed Conditions
Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: bioequivalence determined by statistical comparison Cmax
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- No clinically significant abnormal findings on the physical examination, medical
history, or clinical laboratory results during screening
Exclusion Criteria:
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to Perindopril or any comparable or similar
product.
Locations and Contacts
Novum Pharmaceutical Research Services, Houston, Texas 77042, United States
Additional Information
Starting date: May 2007
Last updated: November 12, 2009
|